Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
ReForm Biologics Announces New Patent for Antibody-Based Therapeutics
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
ReForm Biologics, a pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, expanded its patent portfolio with the issuance of U.S. Patent No. 10,016,513 (the ‘513 patent). The patent, entitled “Stabilizing Excipients for Therapeutic Protein Formulations,” provides ReForm exclusive rights to certain formulations comprising an innovative stabilizer that can significantly reduce protein aggregation and stabilize proteins during storage. This stabilizer offers a promising alternative to conventional polysorbate surfactants.
Polysorbates, the most common surfactants in biologic formulations, are used to prevent therapeutic proteins from adsorbing onto surfaces and interfaces, thereby preventing particle formation. However, polysorbates are known to degrade by hydrolysis, leading to undesirable protein aggregation and surface adsorption. This can produce adverse reactions in patients, such as an immune response to the protein drug. By substituting ReForm’s stable surfactant replacement for polysorbates in biologic formulations, biopharmaceutical companies can reduce protein aggregation and ultimately improve patient care.
“Potential immune responses in patients associated with protein aggregation have become a major concern for regulatory agencies and for innovator and biosimilar companies seeking approval of biotherapeutics,” said John M. Sorvillo, PhD, Chief Executive Officer. “We believe that the use of these new surfactant replacements in the ‘513 patent can allow biopharmaceutical companies to differentiate their formulations, and more importantly, can provide patients safer drug formulations.”
Polysorbates, the most common surfactants in biologic formulations, are used to prevent therapeutic proteins from adsorbing onto surfaces and interfaces, thereby preventing particle formation. However, polysorbates are known to degrade by hydrolysis, leading to undesirable protein aggregation and surface adsorption. This can produce adverse reactions in patients, such as an immune response to the protein drug. By substituting ReForm’s stable surfactant replacement for polysorbates in biologic formulations, biopharmaceutical companies can reduce protein aggregation and ultimately improve patient care.
“Potential immune responses in patients associated with protein aggregation have become a major concern for regulatory agencies and for innovator and biosimilar companies seeking approval of biotherapeutics,” said John M. Sorvillo, PhD, Chief Executive Officer. “We believe that the use of these new surfactant replacements in the ‘513 patent can allow biopharmaceutical companies to differentiate their formulations, and more importantly, can provide patients safer drug formulations.”
